November 17, 2007
Senate Report Criticizes Glaxo's Treatment of Physician Raising Avandia Concerns
Article in the Wall Street Journal -- Glaxo's Handling of Physician Criticized, by Jeanne Whalen. Here's an excerpt:
Over a period of several years, drug maker GlaxoSmithKline PLC was so concerned about a prominent physician's negative views of its diabetes drug that it engaged in a concerted effort to intimidate him and stifle his opinion, a report by the U.S. Senate Finance Committee found.
The report offers a window into the rarely acknowledged practice among drug companies of monitoring and seeking to influence the opinions of leading physicians, who can make or break a drug's sales. The report alleges that Glaxo Chief Executive Jean-Pierre Garnier and former research chief Tachi Yamada were involved in the intimidation.
The Senate Finance Committee released the report Thursday, after researching Glaxo's relationship with John Buse, a diabetes expert and professor of medicine at the University of North Carolina in Chapel Hill. In 1999, Dr. Buse began expressing concerns about the cardiovascular risks of Avandia, one of Glaxo's top selling drugs.
TrackBack URL for this entry:
Listed below are links to weblogs that reference Senate Report Criticizes Glaxo's Treatment of Physician Raising Avandia Concerns: